FDA approves Ionis' TRYNGOLZA (olezarsen) for severe hypertriglyceridemia

 

• Goldman Sachs lifts Ionis Pharmaceuticals price target to $75 while maintaining its Neutral rating on the stock.
• Ionis licenses zilganersen rights outside the U.S. to Recordati for Alexander disease development and commercialization.
• Recordati will pay Ionis a $30 million upfront fee plus potential milestone payments and tiered royalties.

https://finviz.com/stock?t=IONS&p=d